How does octreotide differ from natural somatostatin?

Octreotide is a synthetic analog designed to be more potent and resistant to enzymatic degradation, resulting in a significantly longer half-life compared to the natural hormone.

What are the primary clinical uses of octreotide?

It is primarily used to treat acromegaly, thyrotrophinomas, and symptoms associated with carcinoid syndrome and VIP-secreting tumors.

Does octreotide affect insulin levels?

Yes, octreotide is a potent inhibitor of insulin and glucagon secretion, which can lead to alterations in glucose metabolism in some patients.

Why is octreotide used for diarrhea?

It inhibits the secretion of various gastrointestinal hormones and peptides, which helps reduce fluid and electrolyte output in patients with high-output secretory diarrhea.

Are there different formulations of octreotide?

Yes, octreotide is available as an immediate-release subcutaneous injection and as long-acting release (LAR) depot formulations for sustained therapeutic effect.

What are common side effects associated with octreotide?

Commonly reported side effects include gastrointestinal disturbances, such as gallstone formation, and cardiovascular effects like bradycardia.

Back to Library

Last reviewed: October 2026

Octreotide

Endocrine / Hormonal|Synthetic somatostatin analog

Evidence Snapshot

PubMed-Indexed Literature

9378 exact-name search results

References Reviewed

10 indexed references used for this page

Molecular Record

PubChem CID 448601

Evidence Scope

The evidence base for octreotide is extensive, spanning decades of clinical use in endocrinology, oncology, and gastroenterology, supported by numerous randomized controlled trials and retrospective analyses.

Key Takeaways

Octreotide is a synthetic analog of somatostatin with significantly increased potency and a longer duration of action compared to the endogenous hormone.
It is primarily utilized in clinical settings for the management of acromegaly, thyrotrophinomas, and symptoms associated with carcinoid syndrome and VIPomas.
The drug exerts inhibitory effects on the secretion of growth hormone, insulin, glucagon, and various gastrointestinal peptides.
Pharmacokinetic profiles vary significantly between immediate-release subcutaneous formulations and long-acting release (LAR) depot preparations.
Clinical evidence supports its role in reducing high-output secretory diarrhea and managing specific endocrine-related conditions.

Table of Contents

1.Overview

Octreotide is a cyclic octapeptide that mimics the physiological effects of somatostatin. Because natural somatostatin has a very short half-life (1-3 minutes), octreotide was developed to provide a more stable and potent therapeutic alternative for managing hormone-secreting tumors and endocrine disorders.

2.Mechanism of Action

The mechanism of octreotide is mediated through its high affinity for somatostatin receptors. Upon binding, it triggers inhibitory G-protein signaling, which leads to the suppression of adenylate cyclase and the modulation of intracellular calcium levels. This cascade effectively halts the exocytosis of secretory granules in target endocrine cells.

3.Why Researchers Study It

Current research interest in octreotide extends beyond its traditional endocrine applications. Investigations are ongoing regarding its potential to modulate intestinal homeostasis, inhibit pyroptosis in inflammatory conditions like acute pancreatitis, and improve lymphatic fluid transport. Additionally, researchers are exploring octreotide-derived delivery systems to enhance targeted therapy in oncology.

4.Pharmacology & Molecular Identity

Octreotide is rapidly and completely absorbed following subcutaneous administration. It exhibits a plasma half-life of approximately 1.7 to 1.9 hours, which is substantially longer than endogenous somatostatin. Depot formulations (LAR) allow for sustained release over several weeks. While its primary metabolic pathway involves hepatic and renal clearance, the drug's pharmacokinetics can be influenced by the presence of anti-octreotide antibodies in rare cases.

5.Human Research Evidence

Human evidence is robust, particularly in the treatment of acromegaly, where it has been shown to effectively control serum GH and IGF-1 levels. Clinical trials have also established its efficacy in managing symptoms of carcinoid syndrome and VIPomas. Evidence regarding its use in acute pancreatitis remains controversial, with some studies suggesting clinical benefit while others show mixed results.

6.Preclinical Research

Preclinical studies have utilized octreotide to investigate its role in cellular signaling pathways. Research in animal models has demonstrated that octreotide can attenuate severe acute pancreatitis by inhibiting pyroptosis-related markers and modulating the intestinal microbiota. Other studies have explored its impact on lymphatic vessel function and its potential as a delivery vehicle for targeted cancer therapies.

7.Safety & Research Limitations

Safety observations in clinical literature include reports of bradycardia, conduction abnormalities, and arrhythmias. Gastrointestinal side effects, such as cholelithiasis (gallstones) and steatorrhea, are frequently noted due to the inhibition of gallbladder contractility and pancreatic enzyme secretion. Evidence is limited regarding long-term safety in pediatric populations and specific off-label applications.

8.Evidence Quality & Research Gaps

Significant gaps remain in understanding the precise molecular mechanisms by which octreotide influences non-endocrine conditions, such as lymphatic transport and inflammatory pathways. Furthermore, while its efficacy in endocrine tumors is well-documented, the optimal dosing strategies for emerging off-label uses and the long-term impact of chronic somatostatin receptor modulation require further investigation.

9.Frequently Asked Questions

10.References

1.Stajich GV, Ashworth L. Octreotide. Neonatal network : NN. 2006 Sep-Oct. DOI: 10.1891/0730-0832.25.5.365.PMID: 16989134
2.Fan M, Huang Y, Zhu X, Zheng J, Du M. Octreotide and Octreotide-derived delivery systems. Journal of drug targeting. 2023 Jul. DOI: 10.1080/1061186X.2023.2216895.PMID: 37211679
3.Barrons RW. Octreotide in hyperinsulinism. The Annals of pharmacotherapy. 1997 Feb. DOI: 10.1177/106002809703100217.PMID: 9034427
4.Herrington AM, George KW, Moulds CC. Octreotide-induced bradycardia. Pharmacotherapy. 1998 Mar-Apr.PMID: 9545165
5.Glatard A, Friberg-Hietala S, Keutzer L, Hansson A, Johnsson M. Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly. Clinical pharmacokinetics. 2025 Jul. DOI: 10.1007/s40262-025-01522-3.PMID: 40418492
6.Jablonski SA, Mazepa ASW, Tolbert MK. Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases. Journal of veterinary internal medicine. 2024 Jan-Feb. DOI: 10.1111/jvim.16966.PMID: 38038236
7.Testoni D, Hornik CP, Neely ML, Yang Q, McMahon AW. Safety of octreotide in hospitalized infants. Early human development. 2015 Jul. DOI: 10.1016/j.earlhumdev.2015.04.008.PMID: 25968047
8.Burroughs AK. Octreotide in variceal bleeding. Gut. 1994. DOI: 10.1136/gut.35.3_suppl.s23.PMID: 8206396
9.Cascinu S, Catalano V, Giordani P, Baldelli AM, Agostinelli R. Gastrointestinal cancer refractory to chemotherapy: a role for octreotide? Chemotherapy. 2001. DOI: 10.1159/000049165.PMID: 11275706
10.Karaçavuş S, Kula M, Cihan Karaca Z, Unlühızarcı K, Tutuş A. Octreotide uptake in parathyroid adenoma. Molecular imaging and radionuclide therapy. 2012 Aug. DOI: 10.4274/Mirt.4.PMID: 23487397

Compound Command Center

Linked Research Evidence (0)

Published studies and registry summaries. Trial registration alone is not evidence of efficacy.

No linked research articles yet.